13th week of 2013 patent applcation highlights part 41 |
Patent application number | Title | Published |
20130078242 | Antibodies With Immune Effector Activity And That Internalize In Endosialin-Positive Cells - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments. | 2013-03-28 |
20130078243 | CONJUGATE MOLECULE - This invention relates to a therapeutic molecule capable of suppressing an immune response against an organ or tissue transplantation in a patient. In particular, the invention relates to a conjugate comprising a first portion connected to a second portion, wherein the first portion binds to an MHC Class I molecule and the second portion has HLA-G activity. This conjugate may be used as a medicament to modulate immune responses and induce immunological tolerance specific to allogenic MHC complexes. | 2013-03-28 |
20130078244 | METHODS FOR DETECTING AND REGULATING ALOPECIA AREATA AND GENE COHORTS THEREOF - The invention provides for methods for controlling hair growth by administering a HLDGC modulating compound to a subject. The invention further provides for a method for screening compounds that bind to and modulate polypeptides encoded by HLDGC genes. The invention also provides methods of detecting the presence of or a predisposition to a hair-loss disorder in a human subject as well as methods of treating such disorders. | 2013-03-28 |
20130078245 | ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3 - The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response. | 2013-03-28 |
20130078246 | BIOMARKERS AND METHODS FOR DETECTING AND TREATING SPINAL AND JOINT PAIN - Biomarkers, including isolated fibronectin-aggrecan complexes that correlate with spinal or joint pain and inflammation, and methods for their detection are provided. Also provided are methods for identifying treatment sites in the spine or joint for treatment of pain and inflammation by detecting the presence of, or increased levels of, fibronectin-aggrecan complexes. Methods for treating spinal or joint pain and inflammation are also provided. | 2013-03-28 |
20130078247 | BISPECIFIC BINDING MOLECULES BINDING TO DII4 AND ANG2 - Bispecific binding molecules binding to both DII4 and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with DII4- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described. | 2013-03-28 |
20130078248 | BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2 - Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described. | 2013-03-28 |
20130078249 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 2013-03-28 |
20130078250 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 2013-03-28 |
20130078251 | ANTI-MCSP ANTIBODIES - The invention provides anti-MCSP antibodies and methods of using the same. | 2013-03-28 |
20130078252 | COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 2013-03-28 |
20130078253 | CANCER TARGETS AND USES THEREOF - Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods. | 2013-03-28 |
20130078254 | GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HAEMOPHILUS INFLUENZAE - The invention relates to the polynucleotide sequence of a nontypeable stain of | 2013-03-28 |
20130078255 | SERUM AND TISSUE BIOMARKERS OF HUMAN HCC - The application is based on the surprising finding that proteins regulated by increased c-myc activity in the liver can be used as sis and/or treatment monitoring of cancer and dysplasia, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC), and wherein the proteins are selected from a first group consisting of Polymeric immunoglobulin receptor, Phosphatidylinositol—glycan—specific phospholipase D, Alpha—fetoprotein, Antithrombin 3, Apolipoprotein E, Apolipoprotein M, Fibrinogen beta-chain, Haptoglobin, Paraoxonase 1, Retinol binding protein, Serum amyloid P- component, Transthyretin, or from a second group consisting of Afamin, Glutathione peroxidase 3, Hemopexin, Major urinary protein, Serine protease inhibitor A3K. Consequently, medical uses of said proteins, of corresponding compositions, of corresponding antibodies, of corresponding siRNA and of corresponding nucleotide sequences are claimed. Also claimed are corresponding kits and corresponding methods and procedures. | 2013-03-28 |
20130078256 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS - The invention is related to compounds of Formula (I): | 2013-03-28 |
20130078257 | USE OF AN ACTIVE SUBSTANCE BINDING TO CD28 FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF B-CLL - The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the B-CLL. | 2013-03-28 |
20130078258 | Cachexia Treatment - Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia. | 2013-03-28 |
20130078259 | METHOD OF DIAGNOSING AND PREVENTING PNEUMOCOCCAL DISEASES USING PNEUMOCOCCAL NEURAMINIDASES - A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of | 2013-03-28 |
20130078260 | COMPOUNDS TARGETING THE VEGF AND/OR HIF PATHWAY SUCH AS SORAFENIB OR VATALANIB FOR USE IN THE TREATMENT OF OTITIS MEDIA - The present invention provides a compound which targets the VEGF and/or HIF pathways for use in the treatment and/or prevention of otitis media in a subject. The invention also provides a pharmaceutical composition comprising such a compound and a method for treating and/or preventing otitis media in a subject which comprises the step of administering such a compound or pharmaceutical composition to the subject. | 2013-03-28 |
20130078261 | ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION - The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen. | 2013-03-28 |
20130078262 | FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 2013-03-28 |
20130078263 | Anti-HLA-DR Antibodies Suppress Allogeneic and Xenogeneic Immune Responses to Organ Transplants - Disclosed herein are methods and compositions comprising anti-HLA-DR antibodies for treatment of allogeneic and xenogeneic immune responses occurring in organ transplant rejection and other immune dysfunction diseases. In preferred embodiments, the anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8 | 2013-03-28 |
20130078264 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 2013-03-28 |
20130078265 | LASER-BASED VACCINE ADJUVANTS - The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine. | 2013-03-28 |
20130078266 | Immunosuppression By Blocking T Cell Co-Stimulation Signal 2 (B7/CD28 Interaction) - The invention provides methods for inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 (the B7/CD28 interaction) prevent the activation of xenoreactive T-cells in the recipient. In a first aspect, co-stimulation is prevented by administration to the organ recipient of a soluble form of CTLA-4 from the xenogeneic donor organism. In a second aspect, co-stimulation is antagonised by expressing a ligand for CTLA-4 on the xenogeneic donor cells. In a third aspect, co-stimulation is prevented by expressing recipient organism MHC class II on the surface of the cells of the xenogeneic donor organ. | 2013-03-28 |
20130078267 | Epitopes Related To Coeliac Disease - The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided. | 2013-03-28 |
20130078268 | VACCINE COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to vaccine composition and methods for eliciting a protective immune response in animals against an endogenous peptide of the formula pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe, the composition comprising an immunizing effective amount of said peptide or conjugates thereof. Further, the invention relates to methods of treating cancer, cardiovascular diseases, and increasing life span in an animal, the methods comprising a step of administering to the animal of the vaccine composition of the invention. | 2013-03-28 |
20130078269 | AMYLOID BETA PEPTIDES, ASSEMBLIES THEREOF, AND RELATED METHODS - The present invention provides amyloid β peptide assemblies composed of at least three amyloid β peptide subunits, wherein at least one of the amyloid β peptide subunits is an amyloid β peptide analog. The invention further relates to metal complexes of amyloid β peptide assemblies and the use of amyloid β peptide assemblies as vaccines and in the identification of agents that modulate assembly of the amyloid β peptide subunits. | 2013-03-28 |
20130078270 | HER-2 PEPTIDES AND VACCINES - The present invention provides (a) isolated immunogenic HER-2 peptides capable of inducing immune responses against human HER-2 receptor; (b) isolated nucleic acid molecules encoding an isolated immunogenic HER-2 peptide; (c) plasmid constructs comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; (d) vaccine compositions comprising an isolated immunogenic HER-2 peptide (e) vaccine compositions comprising an isolated nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; and (f) methods of treating or preventing cancer, inhibiting abnormal cell proliferation, or eliciting an immune response against HER-2 protein in a mammal using (1) an isolated immunogenic HER-2 peptide, (2) nucleic acid molecule encoding an isolated immunogenic HER-2 peptide, or (3) a composition comprising an isolated immunogenic HER-2 peptide, or composition comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide. | 2013-03-28 |
20130078271 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection. | 2013-03-28 |
20130078272 | FUNGICIDAL COMPOUNDS AND METHODS OF THEIR USE - Antifungal compounds, an antifungal compound extracted from | 2013-03-28 |
20130078273 | Vault Compositions For Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. | 2013-03-28 |
20130078274 | LIVE, ORAL VACCINE FOR PROTECTION AGAINST SHIGELLA DYSENTERIAE SEROTYPE 1 - The invention relates to | 2013-03-28 |
20130078275 | NOVEL SYSTEMS, VECTORS, AND METHODS FOR DELIVERY OF BIOMOLECULES TO EUKARYOTIC CELLS - Embodiments described herein provide novel bacterial-based methods, systems, and delivery vehicles capable of delivering DNA, RNA, proteins, and other cargo into targeted mammalian cells, both in vitro and in vivo, with high efficiency. Delivery vehicles may be used to deliver molecules such as prophylactic or therapeutic proteins, DNA, shRNA, DNA vaccines, mucosal vaccines, modified viruses or viral components, and other bioactive molecules. Potential applications include gene therapy, wound healing therapies, cancer therapy, immune modulation, and research applications for which delivery of DNA, RNA, proteins, or other cargo into mammalian cells and tissues is required. | 2013-03-28 |
20130078276 | VECTORS EXPRESSING HIV ANTIGENS AND GM-CSF AND RELATED METHODS OF GENERATING AN IMMUNE RESPONSE - The disclosure provides vectors encoding one or more HIV antigens and GM-CSF. Also provided are methods of inducing an immune response in a subject, methods of treating a subject having HIV, and methods of manufacturing a medicament for inducing an immune response that require the use of these vectors and vaccine inserts. | 2013-03-28 |
20130078277 | INFECTIOUS HEPATITIS C VIRUS-HIGH PRODUCING HCV VARIANTS AND USE THEREOF - An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein precursor comprises at least substitution of glutamine at position 862 with arginine, as determined with reference to the amino acid sequence as shown in SEQ ID NO: 2 in the Sequence Listing. | 2013-03-28 |
20130078278 | VACCINE FOR PROTECTION AGAINST SHIGELLA SONNEI DISEASE - Compositions and methods for protecting a susceptable host against an infection of | 2013-03-28 |
20130078279 | FURIN-KNOCKDOWN AND GM-CSF-AUGMENTED (FANG) CANCER VACCINE - Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 2013-03-28 |
20130078280 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA | 2013-03-28 |
20130078281 | ACTIVATORS OF INNATE IMMUNITY - The present invention includes IFNS activating agents that activate expression of IFN-β, activate NF-κB expression, activate an innate immune response, activate the expression of one or more cytokines, and/or induce the expression of interferon beta (IFN-β) through a RNase L and/or MDA5-dependent pathway. Such IFNS activating agents include single stranded RNAs that encode for conserved region II of the L protein of a negative stranded RNA virus, including, but not limited to, viruses of the family Paramyxoviridae. Also included are methods of making and using such IFNS activating agents and compositions and kits including such IFNS activating agents. | 2013-03-28 |
20130078282 | FORMULATIONS DECREASING PARTICLE EXHALATION - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation. | 2013-03-28 |
20130078283 | NOVEL AMPHIPHILES - Disclosed herein is a compound of structure (A): In this compound, X is either O or S, R | 2013-03-28 |
20130078284 | PHARMACEUTICAL FORMULATIONS - The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. | 2013-03-28 |
20130078285 | IMPLANT FOR TISSUE REPAIR - Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5. | 2013-03-28 |
20130078286 | DRUG DELIVERY SYSTEM - The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form. | 2013-03-28 |
20130078287 | PHARMACEUTICAL COMPOSITIONS OF IBUPROFEN AND AN H2 RECEPTOR ANTAGONIST - Pharmaceutical compositions of a H | 2013-03-28 |
20130078288 | Method of Treating Cancer - A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents. | 2013-03-28 |
20130078289 | INDIGESTIBLE POLYMER: STARCH ACETATE -BASED FILM COATINGS FOR COLON TARGETING - A colon targeted delivery dosage form for controlled release of an active ingredient, includes an active ingredient coated in a polymeric mixture of: a water insoluble polymer composition containing at least a starch acetate, and an indigestible polysaccharide composition. The use and method for making the same are also described. | 2013-03-28 |
20130078290 | Gastroretentive Dosage Forms Of GABA Analogs - The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid (“GABA”) analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant. | 2013-03-28 |
20130078291 | BIO-ADHESIVE AGENT COMPRISING SURFACE-MODIFIED HYDROXYAPATITE AND USE THEREOF - The present invention relates to a bio-adhesive agent comprising a surface-modified hydroxyapatite and its use. More specifically, the present invention relates to a bio-adhesive agent for the adhesion between bone and bone, bone and tissue, bone and cartilage, or bone and tendon, or for the adhesion of a shield between bones or of an artificial joint, which comprises a surface-modified hydroxyapatite as an active ingredient, wherein the surface-modified hydroxyapatite is characterized in that a certain linker compound is covalently bonded to the surface of the hydroxyapatite; a method for coating the surface of a metal prosthesis using the surface-modified hydroxyapatite; and a metal prosthesis coated with the surface-modified hydroxyapatite obtained by said method. | 2013-03-28 |
20130078292 | COMPOSITION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME - Provided is a formulation for oral teeth, which includes a plurality of calcium ion carriers and a plurality of calcium-containing particulates. The particulates are carried by the calcium ion carriers, such that the formulation can prevent or rapidly treat dentin-associated symptoms or diseases, while providing a prolonged prophylactic or therapeutic effect. | 2013-03-28 |
20130078293 | HYBRID POWDER OF HALLOYSITE NANOTUBE AND LIGHT-SCATTERING NANOPARTICLE, METHOD FOR PREPARING THE SAME, AND UVSCREENING COSMETIC COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT - The present invention provides a hybrid powder of halloysite nanotubes and light-scattering nanoparticles, a method for preparing the same, and a UV-screening cosmetic composition containing the same as an active ingredient. The hybrid powder of halloysite nanotubes and light-scattering nanoparticles according to the present invention, in which the light-scattering nanoparticles are loaded into the halloysite nanotubes, can prevent the light-scattering nanoparticles from penetrating the skin, which minimizes side effects, and has excellent UV-screening effect. Thus, the hybrid powder of halloysite nanotubes and light-scattering nanoparticles according to the present invention can be effectively used as a UV-screening cosmetic composition. | 2013-03-28 |
20130078294 | Multi-Active Microtargeted Anti-Aging Skin Care Cream Polymer Technology - A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all of the various defined categories of skin aging, including but not limited to wrinkles, abnormal pigment or brown spots due to aging of the skin and an unexpectedly high efficacy in the reduction of redness and acne and rosacea blemishes | 2013-03-28 |
20130078295 | SKIN ANTIAGING TREATMENT - A method for skin antiaging treatment including administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition having a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived peptide, and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant. | 2013-03-28 |
20130078296 | COMPOSITION AND METHOD OF TIME RELEASING ESSENTIAL OILS FOR ANIMAL REPELLENCY AND PESTICIDE USE - The invention is a method of releasing essential oils over at least 30 days which includes encapsulating one or more essential oils in one or more carbohydrate and one or more protein. Additional embodiments include pesticides and/or additional repellents. | 2013-03-28 |
20130078297 | Aqueous Active Ingredient Composition - The invention relates to aqueous active ingredient compositions in which the active ingredient or ingredients are present in the form of an aqueous dispersion of finely divided polymer-active ingredient particles which comprise at least one water-insoluble polymer P, at least one surface-active substance, and at least one organic active crop protection ingredient which is present in the polymer particles and has a solubility in water of not more than 5 g/l at 25° C./101.325 hPa, in which the polymer-active ingredient particles have an average particle diameter, determined by dynamic light scattering, in the range from 300 to 1200 nm, preferably in the range from 310 to 1000 nm, and more particularly in the range from 320 to 800 nm, the polymer P being a polymer of ethylenically unsaturated monomers M which comprise 0.1% to 10%, more particularly 0.2% to 7%, and especially 0.3% to 5%, by weight, based on the total amount of the constituent monomers M of the polymer P, of at least one monoethylenically unsaturated compound M2 which is selected from monoethylenically unsaturated sulfonic acids, monoethylenically unsaturated phosphonic acids, and monoethylenically unsaturated phosphoric monoesters, and also the salts thereof, the amounts in % by weight being based on the acid form of the monomer M2. | 2013-03-28 |
20130078298 | GASEOUS NITRIC OXIDE-SEQUESTERING PRODUCTS AND PROCESSES OF PREPARING SAME - A process of preparing articles having gaseous NO sequestered therein is disclosed, as well as articles prepared thereby. Also disclosed are articles having gaseous NO sequestered therewithin and having reduced amount of oxygen-containing and/or nitrogen-containing reactive species. Also disclosed are processes of preparing packaged articles having a non-gas permeable package that comprises gaseous NO therein and packaged articles made therefrom. Also disclosed are charging devices which can be utilized in the above-described processes. The articles prepared by the above-described processes are preferably medical devices such as indwelling catheters, intubation devices and tampons. Tampons having sequestered therein gaseous NO, uses thereof and processes of preparing same are also disclosed. | 2013-03-28 |
20130078299 | Transdermal Patches Having Ionized Beam Crosslinked Polymers and Improved Release Characteristics - Crosslinked hydrogel-based transdermal pharmaceutical formulations. The hydrogel transdermal formulations. Transdermal patches are useful for administering a variety of drugs to patients. The transdermal patches here employ crosslinked-hydrogels generated through irradiation, thus eliminating any residual effects associated with chemical- or UV-based crosslinking procedures. The transdermal patches may be formed from a variety of high-molecular weight polymeric compounds and include substantial levels of water to improve skin tolerance by the patient. The transdermal patches may also include transcutol as a solvent for the drug, which has been found to increase the effectiveness of drug delivery. The present disclosure also provides for methods of loading a drug into a transdermal formulation after the crosslinking of the hydrogel, thus improving stability and bioavailability through avoiding exposure of the drug to the radiation used in the crosslinking procedure. The transdermal patches here are particularly effective in delivering lidocaine to patients in need thereof. | 2013-03-28 |
20130078300 | BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF - Novel bioabsorbable and/or biocompatible polyurethanes, polyureas, polyamideurethanes and polyureaurethanes with tunable physical, mechanical properties and hydrolytic degradation profiles are provided for use in biomedical applications such as stents, stent coatings, scaffolds, foams, and films. The disclosed polymers may be derived from biocompatible and/or bioabsorbable polyisocyanates. The present invention also relates to new and improved methods for the preparation of the biocompatible and/or bioabsorbable polyisocyanates. | 2013-03-28 |
20130078301 | METHODS FOR STIMULATING GROWTH AND PREVENTING LOSS OF HUMAN HAIR - A method for stimulating hair growth includes providing a topical composition including a purified oil extract from | 2013-03-28 |
20130078302 | Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases - Compositions and methods useful for the inhibition of cancer metastasis are disclosed. | 2013-03-28 |
20130078303 | SOFT-GELATIN CAPSULE FORMULATION - The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 2013-03-28 |
20130078304 | CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS - The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of Zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of Zolpidem or a pharmaceutically acceptable salt thereof. | 2013-03-28 |
20130078305 | Pharmaceutical Compositions For The Coordinated Delivery Of NSAIDs - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 2013-03-28 |
20130078306 | MEDICAMENTS CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE - The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method | 2013-03-28 |
20130078307 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION - A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy. | 2013-03-28 |
20130078308 | ENCAPSULATION DEVICE, MEDICAL CAPSULES, AND ENCAPSULATION METHOD - An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in which the first liquid is injected toward a liquid film of the second liquid retained by the liquid film holder to form a core, the core is wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, and the shell is made in contact with the third liquid to induce chemical reaction. | 2013-03-28 |
20130078309 | ORAL PARTICULATE ANTITUMOR PREPARATION - An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative. | 2013-03-28 |
20130078310 | MULTI-BLOCK COPOLYMERS FOR THE PREPARATION OF STABILIZED MICELLES - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications. | 2013-03-28 |
20130078311 | COMPOSITION FOR TREATING AND/OR PREVENTING OSTEOPOROSIS - The invention relates to a composition comprising deer velvet antler blood (DVAB) in combination with velvet antler for use in the treatment and/or prevention of osteoporosis and a method for treating and/or preventing osteoporosis, comprising administering a therapeutically effective amount of a composition comprising DVAB and velvet antler to a subject at risk of developing or afflicted with osteoporosis. The composition of the invention, when administered to a subject with osteoporosis, increases anti-osteoporotic activity, decreases the biomarker of osteoporosis and recovers the biomechanical strength and structure of bone, suggesting that the said composition could significantly prevent and even treat osteoporosis. | 2013-03-28 |
20130078312 | Biodegradable Putty Compositions and Implant Devices, Methods, and Kits Relating to the Same - Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant. | 2013-03-28 |
20130078313 | MILK DERIVED COMPOSITION AND USE TO ENHANCE MUSCLE MASS OR MUSCLE STRENGTH - The invention relates to the production of compositions containing milk products for use as a nutritional supplement. More specifically, it relates to compositions containing whey growth factor extract, as well as methods for supplementing the nutritional needs of individuals undertaking resistance exercise training. According to one aspect of the invention, there is provided the use of a composition comprising whey growth factor extract, isolated from a milk product by cation exchange chromatography, to increase skeletal muscle strength. | 2013-03-28 |
20130078314 | TRANSDERMAL METHOD OF DELIVERING NUTRIENTS INTO HUMAN BODY - The present invention is about a transdermal method that deliveries nutrients from fresh animal organs to the systemic circulation of the human body by applying the juice or chopped pieces of the fresh animal organs on the skin of the human body and allowing the nutrients to absorb through the layers of the exposed skin. The present invention aims to preserve the Yin and Yang energies naturally present in fresh organs and other foods that are lost in cooking and processing of foods. The present invention uses the full skin area transdermal delivery method by soaking the whole body in the juice of the fresh animal organs as well as the partial skin area transdermal delivery method by exposing certain parts of the human skin area to the fresh juices or chopped fresh animal organs and allowing the nutrients to enter the systemic circulation of the human body. | 2013-03-28 |
20130078315 | EGGSHELL ANTIMICROBIAL AGENT AND METHOD OF USE - Provided herein is a composition and a method for inhibiting bacterial growth. | 2013-03-28 |
20130078316 | METHODS AND COMPOSITIONS FOR IRRIGATION OF MUCOSAL TISSUES - A synthetic endotracheal irrigant for preventing, treating, and reducing infections, including mucosal infections in patients, including infants. A method for producing a formulation of the synthetic endotracheal irrigant with a water content of about 98% (w/w) to about 99.9(w/w) and a total mineral content of less than about 5.0% (w/w), including a sodium content of less than about 2.0% (w/w). The synthetic endotracheal irrigant excludes protein. | 2013-03-28 |
20130078317 | ZINC-CONTAINING COMPOSITIONS FOR THE TREATMENT OF DISEASES, ILLNESSES AND SYNDROMES ASSOCIATED WITH EXPOSURE TO PORE FORMING TOXINS - Embodiments of the invention relate to compositions and methods of using the same to treat conditions caused by exposure to a pore-forming toxin. | 2013-03-28 |
20130078318 | COMBINATION DOSAGE FORMS AND THERAPIES FOR SUPPORTING BONE HEALTH - Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health. | 2013-03-28 |
20130078319 | DETECTION OF OVARIAN CANCER - Among other things, the present disclosure provides a method including the steps of: obtaining a uterine sample; and detecting and/or characterizing in the uterine sample an ovarian cancer biomarker (e.g., CA125). | 2013-03-28 |
20130078320 | COMPOSITION FOR TREATING HEARING LOSS - A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components. | 2013-03-28 |
20130078321 | METHODS FOR TREATING PATIENTS WHO ARE CANDIDATES FOR INHALED NITRIC OXIDE TREATMENT - Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema. | 2013-03-28 |
20130078322 | THERAPEUTIC COMPOSITION PRODUCED USING CAMELLIA SINENSIS LEAVES AND HYDROGEN PEROXIDE - Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities. | 2013-03-28 |
20130078323 | ADAPTOGENIC ACTIVITY OF LABISIA PUMILA EXTRACT - The present invention provides a process of extracting the leaves of | 2013-03-28 |
20130078324 | SPRAY DRIED HUMAN PLASMA - The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. | 2013-03-28 |
20130078325 | Solid Imaging Systems, Components Thereof, and Methods of Solid Imaging - There is provided solid imaging methods and apparatus for making three-dimensional objects from solid imaging material. A tray with a film bottom is provided to hold solid imaging material that is selectively cured into cross-sections of the three-dimensional object being built. A coater bar is moved back and forth over the film to remove any uncured solid imaging material from a previous layer and to apply a new layer of solid imaging material. A sensor is provided to measure the amount of resin in the tray to determine the appropriate amount of solid imaging material to be added, from a cartridge, for the next layer. A shuttle, which covers the tray when the exterior door to the solid imaging apparatus is opened for setting up a build or removing a three-dimensional object, can also be used to move the coater bar and to selectively open one or more valves on the cartridge to dispense the desired amount of solid imaging material. | 2013-03-28 |
20130078326 | EXTRUDER - An extruder comprises an extruding section, a chamber drum, and a forming section. The extruding section kneads and extrudes a kneaded material including a ceramic raw material. The chamber drum includes a first space portion which extends from the extrusion port side of the extruding section in an extruding direction and allows the kneaded material to flow in the extruding direction, and a second space portion which extends from a downstream side of the first space portion in a downward direction, allows the kneaded material to flow in the downward direction different from the extruding direction, and has a discharge port to discharge the kneaded material. The forming section includes a die through which the kneaded material discharged through the discharge port of the chamber drum is pushed out, to extrude and form ceramic formed bodies. | 2013-03-28 |
20130078327 | METHOD OF RECYCLING AIR CONTAINING A STERILIZING AGENT, AND CONTAINER MANUFACTURING PLANT COMPRISING AN AIR RECYCLING CIRCUIT - A container manufacturing plant ( | 2013-03-28 |
20130078328 | Coated Pelletizing Dies - Pelletizing ring extrusion dies comprising a die body having a plurality of holes, wherein each hole has surface at least partially coated with a low-friction coating. The low-friction coatings reduce surface temperatures during operation of the dies, which reduces volatilization and inconsistent flow of the material being extruded. The pelletizing ring extrusion dies possess improved tool life due to the low-friction coatings. | 2013-03-28 |
20130078329 | KNEADING EXTRUDER - A kneading extruder comprises a barrel having an extrusion port through which kneaded material including first and second liquid raw material is extruded, a screw shaft placed in the barrel, the screw shaft kneading the first and second raw material to produce the kneaded material in melted state, a screw driving device continuously rotating the screw shaft at a constant speed, a die communicating with the extrusion port of the barrel, the die having an extrusion port through which the kneaded material in pressurized state is extruded, and an ejection device ejecting a portion of the kneaded material between the extrusion port of the barrel and the extrusion port of the die, the ejection device including ejection quantity regulating means for regulating ejection quantity of the kneaded material so that pressure of the kneaded material at the extrusion port of the barrel is kept constant. | 2013-03-28 |
20130078330 | PRECISION PRESS DEVICE AND PRESS LOAD CONTROL METHOD THEREOF - A precision press device and a press load control method is provided for downsizing a vacuum chamber in press work in the vacuum chamber, shortening a time required to reach a vacuum and performing high accuracy pressure control. A pressure sensor is set up outside the chamber | 2013-03-28 |
20130078331 | COATED PELLETIZING EXTRUSION DIES AND METHOD FOR MAKING THE SAME - A pelletizing extrusion die comprising a die body contains a plurality of extrusion holes. Each of the extrusion holes is defined by a defining surface of the die body wherein at least a portion of the defining surface has a low-friction coating deposited thereon. A method for applying the low-friction coating to the defining surface wherein the applying step occurs at a temperature equal to less than about | 2013-03-28 |
20130078332 | NANOIMPRINTING MOLD AND METHOD FOR PRODUCING THE NANOIMPRINTING MOLD - A nanoimprinting mold having high durability enables reduction of thickness fluctuations in resist. The mold is equipped with a patterned base plate having a patterned region, in which a fine pattern of protrusions and recesses is formed, on a first surface thereof, and a second surface having a 3σ value related to a height difference distribution within a range from 1 nm to 6 nm; a hollowed base plate having a hollowed shape at least at a portion corresponding to the patterned region and a thickness greater than or equal to that of the patterned base plate; and a metal film formed between the patterned base plate and the hollowed base plate so as to bond the second surface of the patterned base plate and a surface of the hollowed base plate that faces the second surface. | 2013-03-28 |
20130078333 | PROCESS FOR PRODUCTION OF REPLICA MOLD FOR IMPRINTING USE - The present invention provides a method for producing a replica mold for imprinting use which is inexpensive and has good properties including strength and flexibility. The method for producing a replica mold according to the present invention comprises the steps of: (A) coating a substrate with an organic-inorganic hybrid material; (B) semi-curing the coated surface with heat and/or an electromagnetic ray to produce a substrate for fine raised and depressed pattern formation; (C) pressing a master mold having a predetermined fine raised and depressed pattern formed thereon against the substrate for fine raised and depressed pattern formation by an imprinting method to transfer the fine raised and depressed pattern onto the substrate; and (D) irradiating the substrate for fine raised and depressed pattern formation onto which the fine raised and depressed pattern is transferred with an electromagnetic ray to cure the substrate. | 2013-03-28 |
20130078334 | PLATE AND APPARATUS FOR FORMING A PLASTIC MATERIAL FLANGED HOLLOW ARTICLE - It is disclosed a plate for a mould station to form a flanged hollow plastic container by shaping a flat billet, the plate comprising a base, a frame, an outer core to form a container of a first size and an inner core to form a container of a second size, smaller than the first size, wherein the frame is integral with the base and wherein the frame defines a frame upper surface; wherein the outer core, in a first configuration, is held elastically with its upper surface flush with the frame upper surface and, in a second moulding configuration, is held with its upper surface recessed with respect to the frame upper surface; wherein the inner core, in a first configuration, is held elastically with its upper surface flush with the frame upper surface and, in a second moulding configuration, is held with its upper surface recessed with respect to the frame upper surface; and wherein a retention system is provided to retain said billet substantially adhering to at least the upper surface of the inner core. | 2013-03-28 |
20130078335 | DEVICE FOR INJECTION-MOULDING A PART - A tooling for injection-molding a part, the tooling including two cavity blocks each including a cavity formed therein of a shape corresponding to a shape of a part that is to be molded once the cavity blocks have been superposed. At least one of the cavity blocks includes a mechanism for positioning a core, which mechanism includes at least one bearing surface for bearing against the core and at least one presser screw screwed into a threaded passage of the cavity block for purpose of holding the core in position against the bearing surface. The tooling further includes a force-limiter limiting force applied to the core by the presser screw. | 2013-03-28 |
20130078336 | Stabilized Edible Emulsions, Methods of Preparation, and Beverages - Stable, edible delivery systems for water miscible or water soluble materials, and aqueous food products such as beverages incorporating such delivery systems are provided. The disclosed delivery systems may be used to isolate a substance otherwise having an unacceptable taste in the food product or to protect a sensitive material in the food, e.g., an ingredient prone to degradation. Methods for producing the delivery systems and aqueous dispersions are also disclosed. | 2013-03-28 |
20130078337 | DISPENSER AND STIRRER - The present invention is an improved device used for storing, dispensing, and stirring beverage additives. The improved tubular shaped dispenser greatly reduces the chance for additive spillage and eliminates the need for additional utensils for transferring and stirring the additive in a beverage. The invention comprises a tubular shaped dispenser body with an internal longitudinal aperture for storing the additive, a dispenser cap, an end cap, a longitudinal top half and bottom half for the dispenser body, and a plurality of perforations on not more than one of said top half and said bottom half of said dispenser body. | 2013-03-28 |
20130078338 | METHOD, KIT, AND CONTAINER FOR PREPARING A SNACK FOOD - A method for preparing a custom flavored snack food includes the provision of a quantity of a snack food that is at least partially cooked and at least one seasoning powder. The snack food is placed in a coating container with the at least one seasoning powder. The snack food is then coated with the at least one seasoning powder. The snack food coated with the at least one seasoning powder is subsequently heated to a predetermined temperature for a predetermined time to form the custom flavored snack food. The method may be practiced with a kit having the snack food, the at least one seasoning powder, the coating container, and the heating container. The heating container may have a removable panel that, when removed, provides access to a heating cavity for receiving and heating the coated snack food to form the custom flavored snack food. | 2013-03-28 |
20130078339 | High Pressure Processing of Pathogenostat-Treated Food Articles - The disclosure relates to method of treating foodstuffs such as whole or cut vegetables or fruits or cuts of meat in a manner that reduces the load of human or other animal pathogens in the foodstuff, preferably without substantially altering its appearance, one or more of its organoleptic properties, or some combination of these. The method includes contacting the foodstuff with a pathogenostatic fluid such as an acidic solution, preferably at a reduced pressure, and thereafter subjecting the foodstuff to an HPP process. Foodstuffs treated in this manner can be packaged in the presence of the pathogenostatic fluid, in the presence of a sauce, or in the presence of substantially no liquid. Packaged foodstuffs treated as described herein exhibit beneficial properties, such as retention of taste, appearance, and texture and extended shelf life, relative to non-treated foodstuffs. | 2013-03-28 |
20130078340 | INFUSIBLE MATERIAL CAPSULE FOR BREWING A BEVERAGE - A sealed capsule for use in apparatus including a capsule receiving station and a water delivery system for brewing a hot beverage in which a hot liquid under pressure infuses a material. A capsule base has a concave bottom floor with angularly spaced structural ribs that form channels for directing brewed beverage to a sharpened spout. A collar surrounds the dispensing spout. A foil attaches to the collar to overlie the spout. A filter lies on the structural ribs. Infusible material lies on the filter. A water distribution plate overlies the infusible material. A cover closes the base unit and includes a water inlet. As the capsule seats in the capsule receiving station, the foil seal is forced over the sharpened spout to rupture and enable brewed beverage to be dispersed. A probe of the water delivery system also penetrates the cover to direct water into the capsule without contacting the infusible material or the brewed beverage. | 2013-03-28 |
20130078341 | Cartridge And Method For The Preparation Of Beverages - A cartridge contains a beverage ingredient which comprises liquid beverage ingredient and elongate particles of beverage ingredient. The cartridge comprises an inlet ( | 2013-03-28 |